Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
about
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerEfficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancerTargeting ALK: Precision Medicine Takes on Drug Resistance.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Understanding the Precision in "Precision Medicine"Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
P2860
Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Re-Evaluating Progression in a ...... ive Non-Small Cell Lung Cancer
@en
Re-Evaluating Progression in a ...... ve Non-Small Cell Lung Cancer.
@nl
type
label
Re-Evaluating Progression in a ...... ive Non-Small Cell Lung Cancer
@en
Re-Evaluating Progression in a ...... ve Non-Small Cell Lung Cancer.
@nl
prefLabel
Re-Evaluating Progression in a ...... ive Non-Small Cell Lung Cancer
@en
Re-Evaluating Progression in a ...... ve Non-Small Cell Lung Cancer.
@nl
P2860
P1433
P1476
Re-Evaluating Progression in a ...... ive Non-Small Cell Lung Cancer
@en
P2093
Emily H Castellanos
Leora Horn
P2860
P304
P356
10.1634/THEONCOLOGIST.2015-0396
P577
2016-04-06T00:00:00Z